

1

2 Robustness of the Dorsal morphogen gradient with respect to morphogen dosage

3

4 Hadel Y. Al Asafen<sup>¶</sup>, Prasad U. Bhandodkar<sup>¶</sup>, Sophia Carrell-Noel<sup>¶</sup>, and Gregory T. Reeves\*

5

6 Department of Chemical and Biomolecular Engineering, North Carolina State University, Raleigh, North

7 Carolina, United States of America

8

9 \* Corresponding author

10 Email: [gtreeves@ncsu.edu](mailto:gtreeves@ncsu.edu)

11

12 <sup>¶</sup> These authors contributed equally to this work.

13

14 **Abstract**

15 In multicellular organisms, the timing and placement of gene expression in a developing tissue assigns the  
16 fate of each cell in the embryo in order for a uniform field of cells to differentiate into a reproducible  
17 pattern of organs and tissues. This positional information is often achieved through the action of spatial  
18 gradients of morphogens. Spatial patterns of gene expression are paradoxically robust to variations in  
19 morphogen dosage, given that, by definition, gene expression must be sensitive to morphogen  
20 concentration. In this work we investigate the robustness of the Dorsal/NF- $\kappa$ B signaling module with  
21 respect to perturbations to the dosage of maternally-expressed *dorsal* mRNA. The Dorsal morphogen  
22 gradient patterns the dorsal-ventral axis of the early *Drosophila* embryo, and we found that an empirical  
23 description of the Dorsal gradient is highly sensitive to maternal *dorsal* dosage. In contrast, we found  
24 experimentally that gene expression patterns are highly robust. Although the components of this signaling  
25 module have been characterized in detail, how their function is integrated to produce robust gene  
26 expression patterns to variations in the *dorsal* maternal dosage is still unclear. Therefore, we analyzed a  
27 mechanistic model of the Dorsal signaling module and found that Cactus, a cytoplasmic inhibitor for  
28 Dorsal, must be present in the nucleus for the system to be robust. Furthermore, active Toll, the receptor  
29 that dissociates Cactus from Dorsal, must be saturated. Finally, the vast majority of robust descriptions of  
30 the system require facilitated diffusion of Dorsal by Cactus. Each of these three recently-discovered  
31 mechanisms of the Dorsal module are critical for robustness. Our work highlights the need for quantitative  
32 understanding of biophysical mechanisms of morphogen gradients in order to understand emergent  
33 phenotypes, such as robustness.

34

## 35 **Author Summary**

36 The early stages of development of an embryo are crucial for laying the foundation of the body plan. The  
37 blueprint of this plan is encoded in long-range spatial protein gradients called morphogens. This positional  
38 information is then interpreted by nuclei that begin to differentiate by expressing different genes. In fruit  
39 fly embryos, the Dorsal morphogen forms a gradient along the dorsal-ventral axis, with a maximum at the  
40 ventral midline. This gradient, and the resulting gene expression patterns are extraordinarily robust to  
41 variations in developmental conditions, even during early stages of development. Since positional  
42 information is interpreted in terms of concentration of the morphogen, one would expect that doubling  
43 or halving dosage would result in disastrous consequences for the embryo. However, we observed that  
44 development remains robust. We quantified the effect of dosage by experimentally measuring the  
45 boundaries of 2 genes, - *sna* and *sog*, expressed along the DV axis and found that variation in the  
46 boundaries of these genes was minimal, across embryos with different dosages of DI. We then used a  
47 mathematical model to discern components of the DI system responsible for buffering the effects of  
48 dosage and found three specific mechanisms – deconvolution, Toll saturation and shuttling

49

## 50 **Introduction**

51 The morphogen concept forms the basis of many models of developing tissues. Through their  
52 concentration gradients in space, morphogens send positional information to cells and direct them to  
53 develop in specific ways depending on their location within a tissue. The roles of these signals range from  
54 the development of the initial polarities of embryos to specification of cell identity in specific tissues, and  
55 the nervous system in both vertebrates and *Drosophila* [1]. Tissue patterning is often initiated by the cells'  
56 concentration-dependent response to the morphogen gradient: cells throughout the tissue are subject to  
57 different levels of morphogen, depending on their position within the field, and accordingly, express

58 distinct target genes. Thus, the quantitative shape of the morphogen gradient is critical for patterning,  
59 with cell-fate boundaries established at specific concentration thresholds. The cells' sensitivity to  
60 morphogen concentration also implies that any shift in the morphogen distribution is expected to result  
61 in an accompanying shift in patterning. Therefore, perturbations to the morphogen dosage or production  
62 rate, which should change the morphogen distribution, should in turn perturb gene expression patterns.  
63 Indeed, early models of morphogen gradient formation assumed the gradient scaled globally with the  
64 morphogen dose (*e.g.*, when one copy of the gene encoding the morphogen is lost, the entire distribution  
65 is divided by two). Such “dosage-scaling” models predicted that catastrophic shifts in target gene  
66 expression domains would occur when the dose of morphogen is altered [2,3]. In contrast, experimental  
67 observations have shown that the spatial positioning of morphogen target genes shift only minimally  
68 when morphogen dosage is perturbed [2–5], with some notable exceptions [6,7]. Thus, there exists a  
69 paradox between the sensitivity of cells to morphogen concentration and the robustness of tissue  
70 patterns with respect to morphogen dose, which implies a mechanism that prevents robust morphogen  
71 gradient systems from scaling with morphogen dose. One such mechanism is self-enhanced ligand  
72 degradation, where the ligand (morphogen) upregulates its own inhibitor, and which has been suggested  
73 to explain experimentally-observed robustness [3,4,8,9]. However, this mechanism does not apply to all  
74 morphogen gradient systems. In particular, the Dorsal/NF- $\kappa$ B signaling network in *Drosophila* embryos  
75 does not clearly exhibit the self-enhanced degradation mechanism.

76 The NF- $\kappa$ B module, conserved from flies to humans, is implicated in several cellular  
77 responses/phenotypes, including tissue patterning, inflammation, innate immunity,  
78 proliferation/apoptosis, and cancer [10–14]. The maternal transcription factor Dorsal (Dl), homologous to  
79 mammalian NF- $\kappa$ B, patterns the dorsal-ventral (DV) axis of the developing *Drosophila melanogaster*  
80 embryo to specify mesoderm, neurogenic ectoderm, and dorsal ectoderm cell fates (Roth et al., 1989;  
81 reviewed in [16–18]). In the early embryo, Dl protein is initially uniformly distributed around the DV axis.

82 During nuclear cleavage cycle (nc) 10, the nuclei migrate to the periphery of the syncytial blastoderm and  
83 the Dl gradient begins to be established. The I $\kappa$ B homolog Cactus (Cact), which is also maternally-supplied,  
84 binds to Dorsal, retaining it outside the nuclei. Toll, the *Drosophila* homolog of the Interleukin 1 receptor,  
85 is active on the ventral side of the embryo, where it signals through Pelle kinase to phosphorylate the  
86 Dl/Cact complex [19], which results in dissociation of Dl from Cact, allowing Dl to enter the nuclei, where  
87 it regulates gene expression. Because Toll signaling is spatially asymmetric, a nuclear gradient of Dl forms,  
88 with a peak at the ventral midline and a Gaussian-like decay in space to become nearly flat at  
89 approximately 45% of the embryo's circumference (**Figure 1A**) [5,20]. From 45% to 100% ventral-to-dorsal  
90 coordinate, the gradient has a shallow downward slope to achieve non-zero basal levels at the dorsal  
91 midline [5,20,21]. Our computational studies have suggested the non-zero basal levels are primarily  
92 composed of Dl/Cact complex in the dorsal-most nuclei, not free Dl [22].

93 As shown in **Figure 1B**, different genes are turned on at different concentrations of Dl [16,23]. It can be  
94 both an activator and a repressor of transcription. At high concentrations of Dl on the ventral side of the  
95 embryo, high threshold genes such as *snail* (*sna*) are expressed. In the lateral part of the embryo,  
96 intermediate Dl levels activate the expression of low threshold genes such as short gastrulation (*sog*). The  
97 domains of these genes can be quantified using measurements of the dorsal border and ventral border  
98 (**Fig 1C**).

99 While the copy number of maternal *dl* has been shown to affect the Dl gradient and downstream tissue  
100 structure, the phenotypes are subtle. Embryos from mothers heterozygous for a *dl* null allele (1x *dl*) have  
101 shorter, wider, and flatter Dl gradients as compared to wildtype [5,24–26]. While these embryos have a  
102 weakly dorsalized phenotype, female flies with a half dose of *dl* produce a high fraction of viable progeny  
103 at room temperature [27,28]. Furthermore, measurements in a handful of embryos ( $n < 12$ ) found no  
104 statistical shift in the *sog* expression domain [5], and a shift of roughly only one cell diameter in the *sna*  
105 domain [26]. The altered shape of the Dl gradient has recently been attributed to a combination of two

106 novel observations. First, Cact acts to facilitate the diffusion of Dl (i.e., “shuttling” of Dl by Cact), which  
107 results in a net flux of Dl to the ventral side of the embryo [26]. And second, active Toll receptor complexes  
108 are saturated by Dl/Cact complex [26]. Together, these processes act to accumulate Dl on the ventral side  
109 in wildtype embryos, but accumulate Dl in ventral-lateral regions in 1x *dl* embryos. Furthermore,  
110 experimental evidence strongly suggests the shuttling mechanism is required for viability of 1x *dl* embryos,  
111 as embryos from heterozygous *dl* mothers that also have compromised shuttling are non-viable [26].

112 In a similar manner, embryos with overexpression of excess, transgenic copies of *dl* (4x *dl*) are only weakly  
113 ventralized, and a large fraction still hatch [29]. Given the subtlety of the 1x and 4x *dl* phenotypes, and  
114 the viability of the embryos, one may ask whether this implies the Dl gradient system is robust, and if so,  
115 whether the robustness requires special mechanisms, such as shuttling and Toll saturation [26]. As  
116 mentioned above, dosage-scaling models are typically sensitive to dosage; however, such a model of the  
117 Dl gradient has not been analyzed for robustness of gene expression with respect to variations in  
118 morphogen dosage.

119 In this work, we used empirical and computational modeling, together with quantitative measurements  
120 of the Dl gradient and domains of target gene expression, to investigate the robustness of the Dl gradient  
121 system with respect to dosage of maternal *dl*. First, we showed that a dosage-scaling formulation of the  
122 Dl gradient has an unacceptably high sensitivity to the maternal dosage of *dl*, even in the best-case  
123 scenario, in which basal levels are composed primarily of Dl/Cact complex and there is negligible Dl activity  
124 at the dorsal midline [22]. In particular, in the absence of a mechanism to prevent dosage-scaling, doubling  
125 or halving the maternal *dl* dosage is predicted to result in drastic perturbations to gene expression. Next,  
126 we experimentally measured gene expression domains and the Dl gradient width in embryos from  
127 mothers with *dl* dosages of 1x (heterozygous null for maternal *dl*), 2x (wildtype), and 4x (expressing two  
128 copies of a *dl* rescue construct; Carrell et al., 2017; Reeves et al., 2012) and showed that, in contrast to  
129 the predictions of the dosage-scaling model, the perturbations to patterns are minimal. To identify the

130 possible mechanism for this robustness, we analyzed a computational model of the Dl/Cact system. Our  
131 model is based on previously published models in which Dl and Cact can interact, enter the nuclei, and  
132 diffuse between “cytoplasmic compartments” surrounding the nuclei [21,22,24,26,30]. The active Toll  
133 signaling complex, which is limited to the ventral side of the embryo, acts as a Michaelis-Menten-like  
134 enzyme to favor dissociation of the Dl/Cact complex. We constrained the model using our measurements  
135 of Dl target gene expression in 1x, 2x, and 4x embryos. A random parameter search showed that several  
136 parameter sets resulted in robust phenotypes. Our analysis of the robust parameter sets showed that  
137 robustness can rarely be achieved unless (1) the free Dl nuclear levels drop to near zero on the dorsal side  
138 of the embryo [22], (2) significant facilitated diffusion by Cact occurs [26], and (3) active Toll signaling can  
139 be saturated by Dl/Cact complex [26]. Quantitative analysis can be used to assess rigorously the  
140 robustness of different patterning models. Applying the same modelling principles to other systems might  
141 identify additional mechanisms that underlie robust patterning by morphogen gradients in development.

## 142 **Results**

### 143 *Sensitivity of a dosage-scaling model of the Dl gradient*

144 Early models of morphogen gradients exhibited “dosage-scaling,” in that these descriptions of the  
145 morphogen gradient scaled globally, in a multiplicative manner, with morphogen dosage. Morphogen  
146 gradients predicted by these models were highly sensitive with respect to morphogen dosage [3,31,32].  
147 However, these models focused on exponential-like morphogen distributions, whereas the Dl gradient is  
148 Gaussian-shaped [5,20,26]. Therefore, to determine the extent to which the robustness of the Dl system  
149 may be inherent to the Gaussian shape of the Dl gradient, versus how much of the robustness requires a  
150 special mechanism, we analyzed an empirical, dosage-scaling description of the gradient.

151 Let  $c(x)$  be the distribution of nuclear Dl as a function of the DV coordinate  $x$ :

152 
$$c(x) = \alpha \left[ \exp\left(-\frac{x^2}{2\sigma^2}\right) + m|x| + b \right], \quad (1)$$

153 where  $\alpha$  is a proportionality constant related to morphogen dosage,  $\sigma$  represents the spatial width of the  
154 DI gradient,  $m$  is the shallow, downward slope of the DI gradient tail, and  $b$  represents the basal levels of  
155 the gradient, related to the levels of DI that is present in the dorsal-most nuclei. From empirical  
156 measurements,  $b \approx 0.4$  and  $m \approx -0.1$  [20].

157 To calculate the robustness of the predicted gene expression boundaries with respect to changes in  $\alpha$ , we  
158 performed a sensitivity analysis. Let the sensitivity coefficient of a gene expression border with respect to  
159 maternal *dl* dosage be defined as  $\phi \equiv (\partial \ln x_g / \partial \ln \alpha)_{\theta}$ , where  $x_g$  is the location of gene expression  
160 boundary and  $\theta$  is the threshold in DI nuclear concentration required to express the gene (see Materials  
161 and Methods for more information). We found the model of the DI gradient described by Eqn (1) has  
162 unacceptably high values of the sensitivity coefficient ([Fig. 2A](#)). As a rule of thumb, sensitivity coefficients  
163 should be designed to be 0.3 or less [32,33]; the gradient described by Eqn (1) has sensitivity coefficients  
164 of one or greater.

165 Previously, it was found that a model in which both DI and DI/Cact complex are present in the nucleus was  
166 more consistent with experimental results than one in which only free DI is allowed to enter the nucleus  
167 [22]. This model was also more robust to noise in DI levels. Therefore, we asked whether empirically  
168 modeling the presence of DI/Cact complex in the nuclei could also improve the predicted robustness with  
169 respect to maternal *dl* dosage. In this case, Eqn (1) represents the sum of the two DI-containing species.  
170 Deconvolution of the non-functional DI/Cact contribution from the sum would result in the active, “true”  
171 DI gradient (i.e., free DI). Our previous work has suggested the DI/Cact contribution is roughly constant  
172 across the DV axis [22], so that empirically, the active DI gradient can be modeled by Eqn (1) with a much  
173 lower value of  $b$ . If we set  $b = 0.11$ , so that the intensity of free nuclear DI in the dorsal-most nuclei is 1%  
174 of the intensity in the ventral-most nuclei, the sensitivity of gene expression is improved markedly ([Fig.](#)



175 [2A](#)). However, even in this best-case scenario, the minimum sensitivity coefficient (located at  $x_g = 0.34$ )  
176 remains unacceptably high, roughly 0.4, while gene expression boundaries located elsewhere experience  
177 even higher sensitivities.

178 To put the problem in more experimentally concrete terms, we can use Eqn (1) to predict the outcome of  
179 deleting one copy of maternal *dl* (1x *dl*), or expressing two extra copies (4x *dl*). Let  $\alpha = 1$  to represent the  
180 wildtype dosage of maternal *dl*, so that  $\alpha = 0.5$  and  $\alpha = 2$  represent the 1x and 4x embryos, respectively.  
181 In the perturbed cases, the predicted DV gene expression profile in the embryo would result in lethality:  
182 1x embryos completely lose *sna* expression, while 4x embryos have a highly expanded domain of *sna* and  
183 lose *dpp* completely ([Fig. 2B](#)). As with the sensitivity coefficient above, if *b* is lowered, the effects on gene  
184 expression are less severe ([Fig. 2C](#)). However, the empirical model still predicts lethality: 1x embryos  
185 express *sna* in < 10% of the DV axis [26], and 4x embryos have severely reduced *dpp* expression. We  
186 conclude that robustness does not arise simply from a Gaussian shape in a dosage-scaling context, and  
187 thus, there must be a mechanism by which the embryo compensates for changes in the maternal *dl*  
188 dosage.

189

### 190 *Robustness of Dl-dependent gene expression*

191 While the dosage-scaling model predicted high sensitivity of gene expression, limited measurements of  
192 gene expression in 1x and 4x embryos [5,26], as well as their viability [27–29], suggest the system is robust.  
193 To more accurately quantify the robustness of Dl target gene expression with respect to *dl* dosage, we  
194 performed large sample size measurements (generally  $n \sim 40$  or greater) of the expression of two Dl  
195 target genes, *sna* and *sog*, in 1x, 2x, and 4x embryos. We found that, with only one exception, the  
196 expression domains of both genes in 1x and 4x embryos were statistically different from their expression  
197 in 2x (wildtype) embryos ( $p\text{-val} \leq 2 \times 10^{-4}$ ; [Fig 3](#)). The lone exception, the *sna* border in 4x embryos, had a

198 much smaller sample size than the rest ( $n = 13$ ). Furthermore, the direction of the shifts in gene expression  
199 boundaries were as one might expect: in 1x embryos, the gene expression domains shifted closer to the  
200 ventral midline, while in 4x embryos, they shifted more dorsally.

201 Even though we were able to measure statistically significant differences from wildtype, the shifts in gene  
202 expression borders were minimal (roughly 10% or less; see Table 1), in contrast to the predictions of the  
203 dosage-scaling model (Eqn 1). Therefore, our quantification of the robustness of gene expression domains  
204 further suggests that a mechanism exists to mitigate the effects of altering the dosage of maternal *dl*. We  
205 suspected that this mechanism could be traced to the shape and width of the DI gradient in 1x, 2x, and 4x  
206 embryos.

207

#### 208 *Robustness of the DI gradient*

209 Previously, it has been shown that a half maternal dose of *dl* significantly shortens and widens the DI  
210 gradient, and results in a flattened, and sometimes double-peaked, top [5,24–26]. Given that this outcome  
211 cannot be predicted by the non-robust dosage-scaling description, in which the width and shape of the  
212 gradient do not change with dosage, we asked whether such changes to the DI gradient would be  
213 sufficient to confer robustness to predicted gene expression. Therefore, we measured the DI gradient in  
214 embryos loaded with 1x, 2x, and 4x copies of maternal *dl* (see [Fig. 4A](#) and Table 1). As previously reported,  
215 1x embryos had a wider and flatter DI gradient [5,26]. However, the previously-reported width  
216 measurements for 1x embryos cannot be directly compared to widths in wildtype embryos, given the  
217 width measurements are based on the assumption that the DI gradient is Gaussian-shaped, which the 1x  
218 DI gradient is not. Accounting for the differing shape (see Supplementary information), the 1x DI gradient  
219 measures as narrower than wildtype ([Fig. 4B](#)).

220 When we examined 4x embryos , we found the gradient became statistically wider (Table 1; [Figs. 4 A,B](#)),  
221 which also defies a dosage-scaling description of the DI gradient. However, rather than explaining the  
222 robustness of the DI system, these measurements naïvely predict even higher sensitivities than the  
223 dosage-scaling model. Consider the basic expectation that the 1x gradient should have a roughly 50%  
224 lower amplitude than wildtype, while the 4x gradient should have a roughly 200% higher amplitude, even  
225 if the gradients are not the exact shape and width as wildtype. The combination of decrease in gradient  
226 amplitude and decrease in gradient width in 1x embryos, or an increase of both in 4x embryos, would  
227 likely result in sensitive DI-dependent gene expression, as the two effects (amplitude and width)  
228 exacerbate each other. In contrast, the dosage-scaling model has only one effect: a changing gradient  
229 amplitude.

230 One way to explain the robustness of gene expression, given the observed changes in DI gradient shape  
231 and width, would be if the amplitudes of the 1x and 4x gradients significantly departed from expectation.  
232 Therefore, we computed the amplitudes for the 1x and 4x gradients, with respect to the 2x gradient  
233 (which was set to an amplitude of one), that would most closely predict the experimentally observed gene  
234 expression in these embryos ([Fig. 4C](#); see Supplementary Methods). We found that a 1x gradient with >  
235 50% of the wildtype amplitude, and a 4x gradient with < 100% of the wildtype amplitude, would be  
236 consistent with the experimentally observed robust gene expression. While it is unlikely the 4x gradient  
237 would have a shorter amplitude than the 2x gradient, values slightly greater than one are also acceptable  
238 ([Fig. 4D](#)).

239 These results suggest that the mechanism to impart robustness with respect to morphogen dosage can  
240 control the width, shape, and amplitude of the DI gradient. Our previous work has shown that facilitated  
241 diffusion, also known as shuttling, combined with saturation of the active Toll receptor, can produce the  
242 wider, flatter gradients observed in the 1x embryos [26]. Given the saturation of the active Toll receptor,  
243 this same mechanism may allow for negligibly taller DI gradients in 4x embryos. Furthermore, we have

244 seen that 1x embryos that also have compromised shuttling are non-viable [26]. Therefore, to test  
245 whether such a combination of mechanisms – shuttling and Toll saturation, together with deconvolution  
246 ([Fig. 2C](#)) – can grant the DI gradient system robustness with respect to maternal *dl* dosage, we analyzed a  
247 mechanistic model capable of capturing these mechanisms.

248

#### 249 *Computational modeling of DI gradient sensitivity*

250 The model of DI/Cact interactions analyzed here is based on previous models of the DI gradient  
251 [22,24,26,30]. In particular, we assume that DI, Cact, and DI/Cact complex can bind, diffuse, and enter and  
252 exit the nucleus; and that Toll signaling can be modeled using a Michaelis-Menten-like formulation (see  
253 Methods and Eqns 2-4) [26]. Using this model, we performed a random parameter search to screen for  
254 parameter sets in which the DI nuclear gradient was robust to changes in maternal *dl* dosage ([Fig. 5 A-G](#),  
255 see Methods for more details).

256 We found three trends in the parameter sets necessary for robustness. First, all robust parameter sets  
257 predicted that the free DI nuclear intensity drops to near zero on the dorsal side of the embryo, a result  
258 consistent with the deconvolution hypothesis that suggests that DI fluorescence, as observed in  
259 immunostaining experiments or in live embryos expressing DI-GFP, represents both free DI and DI/Cact  
260 complex, and that it is important to distinguish between the two [22]. This observation may be similar to  
261 the result seen in [Fig. 2C](#), in which decay of the DI gradient to zero at the dorsal midline improved  
262 robustness. [Fig. 5A](#) shows the concentration gradient of free DI for all three values of dosage (1x, 2x, 4x)  
263 for one of the robust parameter sets; it can be seen that all concentration curves fall to zero around lateral  
264 regions of the embryo. These same parameter sets predict a gradient of DI/Cact complex that is non-zero  
265 at the dorsal midline (S1 Fig), suggesting that, in these simulated embryos, direct fluorescence  
266 measurements (the sum of DI and DI/Cact in the nucleus) would reveal what appears to be a non-robust

267 DI gradient. Furthermore, the model does not universally predict that the DI gradient decays to zero at  
268 the dorsal midline. While all robust parameter sets do so, many rejected parameter sets do not (S2 Fig).  
269 Thus, the model results strongly suggest deconvolution is necessary for robustness.

270 Second, we found that the effective diffusivity of DI/Cact complex is greater than that of free DI in nearly  
271 all robust parameter sets. As the flux of DI/Cact complex is ventrally directed (i.e., shuttling), this result  
272 implies that there is a net flux of DI from dorsal to ventral regions [26]. We plotted the distribution of the  
273 ratio of the effective diffusivity of DI/Cact complex to that of free DI, henceforth called ratio of length  
274 scales ( $\rho$ ), in [Fig. 5B](#). In over 95% of the robust parameter sets, this ratio was found to be greater than  
275 one. Thus, the constraint of robust gene expression rejects most parameter sets that do not entail  
276 facilitated diffusion of DI by Cact.

277 Finally, the model also suggests that saturation of Toll receptors is necessary for robustness of gene  
278 expression. In all robust parameter sets, the saturation constant for Toll signaling,  $\kappa$ , was between 0.001  
279 and 2. Indeed, as seen in [Fig.5C](#),  $\kappa$  was the most tightly constrained parameter, which implies tight  
280 regulation of Toll saturation may be the most important aspect of the mechanism to ensure robustness  
281 of gene expression. This shows that the constraints in the model overwhelmingly favor saturation of Toll  
282 receptors by the DI/Cact complex, as the concentration of DI/Cact complex in our equations has been  
283 scaled to be of order 1. Taken together, these modeling results suggest that the mechanisms of  
284 deconvolution and Toll saturation are necessary for a robust DV system, while shuttling of DI by Cact  
285 greatly improves the chances of robustness [22,26].

286

### 287 *Model predictions of amplitude ratios*

288 In addition to endorsement of the above three mechanisms, the model makes a specific prediction  
289 regarding the ratios of amplitudes of the 1x and 4x embryos to that of the wildtype (2x). As seen in [Fig. 5](#)

290 [D,E](#) the ratio of amplitudes of 1x embryos:2x embryos is overwhelmingly favored to be greater than 0.5  
291 but less than 0.9, and that of 4x embryos:2x embryos is favored to fall between 1 and 1.55.

292 It can be seen from [Fig. 5 D,E](#) that as the value of  $\kappa$  decreases (and thus, Toll becomes more saturated),  
293 the range of amplitude ratios available to robust descriptions of the DI gradient increases. For lower values  
294 of  $\kappa$ , a range of 1.1 to 1.6 is accepted by the model for ratio of amplitudes of 4x embryos:2x embryos and  
295 a range of 0.5 to 0.85 for ratio of amplitudes of 1x embryos:2x embryos. At higher values of  $\kappa$ , the values  
296 of the amplitude ratios for 4x/2x and 1x/2x seem to converge to 1.45 and 0.57 respectively, meaning that  
297 as Toll is more easily saturated (lower values of  $\kappa$ ), the model allows for a small, but noticeable range of  
298 amplitude ratios for varying dosages. This result seems to indicate that under constrained conditions of  
299 Toll saturation, only particular peak amplitudes are preferred – about 1.55 times the wildtype value for  
300 4x embryos and about 0.57 times the wildtype value for 1x embryos. However, if Toll receptors saturate  
301 easily, an appreciable range of amplitude ratios leads to robustness. Thus, Toll saturation seems to be an  
302 inherent mechanism for robustness in the embryo.

303 In a similar way, the model predicts that the extent of shuttling of DI by Cact also affects the acceptable  
304 values of the amplitude ratios. In [Fig. 5 F,G](#) we plotted amplitude ratios against ratio of length scales, and  
305 we see that when facilitated diffusion by Cact does not occur (about 5% of parameter sets), the amplitude  
306 ratios of 4x/2x and 1x/2x are constrained around 1.45 and 0.57, respectively. The values of amplitudes  
307 seem to converge to similar values when Toll saturation was minimal. On the other hand, when the length  
308 scale ratio is greater than 1, a wider range of amplitude ratios are accessible to the embryo.

309 Thus, it seems that both Toll saturation and shuttling of DI from dorsal to ventral regions allows the  
310 embryos to explore a wider range of amplitude ratios, which allows greater flexibility for robustness.  
311 However, when the above mechanisms are constrained, the amplitude ratios must take on specific values,  
312 which in turn makes it difficult to achieve robustness.

313

## 314 **Discussion**

315 Animal development is a complex process that must be buffered against myriad environmental,  
316 nutritional, and genetic perturbations. The robustness of development with respect to these  
317 perturbations often requires regulatory mechanisms. Here we investigated the robustness of gene  
318 expression in the early *Drosophila* embryo with respect to variations in the maternal gene dosage of the  
319 NF- $\kappa$ B transcription factor Dorsal in a quantitative and computational manner. The NF- $\kappa$ B pathway is  
320 highly conserved and is centrally involved in a diverse array of cellular processes, including inflammation,  
321 apoptosis, and innate immunity. In flies, DI/NF- $\kappa$ B also directs embryonic development and  
322 differentiation. However, essential questions related to NF- $\kappa$ B robustness in *Drosophila* remain  
323 unresolved. Our analysis of an empirical, dosage-scaling description of the DI gradient, together with  
324 detailed measurements of the DI gradient and its target genes, suggest that a mechanism to control the  
325 shape, width, and amplitude of the DI gradient is necessary for robustness. Our previous work found three  
326 novel mechanisms in the establishment of the DI gradient: deconvolution, shuttling, and Toll saturation  
327 [22,26]. In this paper, we used a computational model to study the importance of each of these  
328 mechanisms for the robustness of the DI system.

329 Recent work showed the importance of deconvolving experimentally-measured fluorescence signal into  
330 free DI and bound DI (DI/Cact complex) when interpreting the DI gradient [22]. Doing so results in a nuclear  
331 DI gradient that drops to near zero instead of to non-zero basal levels at dorsal regions [5,15,20,21]. In  
332 the dosage-scaling model, deconvolution was modeled by setting basal levels to near zero. While this  
333 choice of basal levels improved robustness somewhat in the dosage-scaling model, the gene expression  
334 boundaries remained overly sensitive to *dl* dosage. Furthermore, every robust parameter set in the  
335 computational model predicted a free DI gradient that decayed to near zero, whereas non-robust

336 parameter sets did not. Thus, while deconvolution by itself is not sufficient to explain the robustness of  
337 gene expression boundaries, it appears to be a necessary piece.

338 Our model also suggests the shuttling mechanism increases robustness of the DI system. In such a  
339 mechanism, Toll signaling creates a sink for DI/Cact complex, which establishes a ventrally-directed flux  
340 to accumulate DI in ventral regions. While it is possible that free DI then diffuses dorsally, such counter-  
341 diffusion is likely mitigated by capture of free DI by the nuclei. Previous work in our lab suggests that  
342 shuttling of DI/Cact complex from dorsal to ventral regions is an important factor for robustness in the  
343 embryo [26]. Our model supports this result, as most parameter sets that selected for robust gene  
344 expression favored facilitated diffusion of DI by Cact, as the effective diffusivity of DI/Cact was higher than  
345 that of free DI.

346 Previous work also suggested that, in wildtype embryos, active Toll receptors are limiting [26], thereby  
347 maintaining robust gene expression, even when *dl* dosage varies from wildtype. In wildtype embryos,  
348 when active Toll signaling complexes are saturated with DI/Cact complex, a significant number of DI/Cact  
349 complexes bypass the ventral-lateral regions without being dissociated, and DI is shuttled to the ventral-  
350 most portions of the embryo. On the other hand, if active Toll signaling complexes are not saturated, as  
351 may be the case in 1x embryos, the DI/Cact complex will be dissociated at a higher rate in the ventral-  
352 lateral regions of the embryo and will be unable to reach the ventral-most regions of the embryo. The lack  
353 of Toll saturation in 1x embryos thus results in a flatter and wider concentration gradient of nuclear DI.

354 While embryos with 4 copies of *dl* have double the wildtype DI dose, twice as much DI will not necessarily  
355 enter the nuclei because that process relies on Toll signaling, which may be saturated. Similarly,  
356 decreasing the *dl* dosage, as in the case of 1x embryos, implies halving the amount of DI/Cact complex  
357 without reducing the absolute number of free DI molecules that will enter the nuclei. If the active Toll



358 complexes remain constant in all three cases of dosage and provided that they are saturated, only minor  
359 variations occur in the concentration of free DI when dosage changes ([Fig 5A](#)).

360 In this work we have demonstrated the importance of certain built-in mechanisms within the early  
361 *Drosophila* embryo that ensure robustness of gene expression along the DV axis. These three mechanisms,  
362 (deconvolution of the measured DI fluorescence into free DI and DI/Cact complex, saturation of Toll  
363 receptors by DI/Cact complex, and shuttling of DI by Cact from dorsal to ventral regions of the embryo)  
364 are crucial for ensuring that genes expressed in the DV axis have domain boundaries in specific regions.  
365 We have presented both experimental and computational evidence that these processes are paramount  
366 for safeguarding against genetic perturbations to *dl* dosage. The advances in studying the molecular  
367 mechanism behind robustness with respect to maternal *dl* dosage may open the door for understanding  
368 the question of how sustained embryonic development can be achieved despite genetic and  
369 environmental fluctuations.

370

371

## 372 **Methods**

### 373 *Fluorescent in situ Hybridization*

374 All embryos were aged to NC 14 (approx. 2-4 hours after egg lay), then fixed in 37% formaldehyde  
375 according to standard protocols [34]. A combination fluorescent *in situ* hybridization/fluorescent  
376 immunostaining was performed according to standard protocols [34]. Briefly, fixed embryos were washed  
377 in PBS/Tween and hybridized at 55 °C overnight with anti-sense RNA probes, which were generated  
378 according to standard lab protocol. The embryos were then washed and incubated with primary  
379 antibodies at 4 °C overnight. The next day, they were washed and incubated for 1-2 hrs with fluorescent

380 secondary antibodies at room temperature. The embryos were then washed and stored in 70% glycerol  
381 at -20 °C. Embryos were imaged within one month of completing the protocol.

382 Antibodies used were anti-dorsal 7A4 (deposited to the DSHB by Ruth Steward (DSHB Hybridoma Product  
383 anti-dorsal 7A4)) (1:10), donkey anti-mouse- 488 (Invitrogen A21202, Lot 81493) (1:500), rabbit anti-  
384 histone (abcam ab1791, Lot 940487) (1:5000), donkey anti-rabbit-546 (Invitrogen A10040, Lot 107388)  
385 (1:500), goat anti-biotin (ImmunoReagents, Raleigh, NC, GtxOt-070-D, Lot 19-19-112311) (1:50,000),  
386 donkey anti-goat-647 (Invitrogen A21447, Lot 774898) (1:500), goat anti-fluorescin (Rockland 600-101-  
387 096, Lot 19458) (1:500), rabbit anti-fluorescin (Life Technologies A889, Lot 1458646) (1:500), goat anti-  
388 histone (Abcam, ab12079, Lots GR6952-4 and GR129411-1) (1:100), donkey anti-rabbit-350  
389 (ImmunoReagents, DkxRb-003-D350NHSX) (1:500). For some experiments the nuclear stain Draq5 (Cell  
390 Signaling #4084S) was used instead of an anti-histone antibody.

391

#### 392 *Mounting and Imaging of Fixed Embryos*

393 Embryos were cross sectioned and mounted in 70% glycerol as described previously [35]. Briefly, a razor  
394 blade was used to remove the anterior and posterior thirds of the embryo, leaving a cross section roughly  
395 200 µm long by 200 µm in diameter. These sections were then oriented such that the cut sides became  
396 the top and bottom. Sections were then imaged at 20x on a Zeiss LSM 710 microscope. 15 z-slices 1.5 µm  
397 apart were analyzed, for a total section size of 21 µm.

398

#### 399 *Image analysis*

400 Images of embryo cross sections were analyzed using a previously derived algorithm [36]. Briefly, the  
401 border of the embryo was found computationally, then the nuclei were segmented using a local

402 thresholding protocol. The intensity of dl in each segmented nucleus was calculated as the ratio between  
403 the intensity in the dl channel divided by the intensity in the nuclear channel. The intensity of mRNA  
404 expression was calculated as average intensity within an annulus roughly 18  $\mu\text{m}$  wide around the  
405 perimeter of the embryo. mRNA profiles were fit to canonical parameters; those with a goodness of fit  
406 (gof) less than 0.7 were omitted from study.

407 All dl gradients were fit to a Gaussian, and these fits were used to determine the width parameter,  $\sigma$ .  
408 Gradients with a gof less than 0.8 were eliminated from the results. Normalized intensity plots were  
409 generated by fitting each embryo's data to its own Gaussian by subtracting the B value and 70% of the M  
410 value, then dividing by the A value. ( $X = (x - B - 0.7M)/A$ ). The average normalized intensity plot was  
411 generated by averaging the plots of all embryos in the specified genotype.

412 Multiple experiments with statistically similar wild type controls were analyzed simultaneously to  
413 generate the data in this report. Statistical significance was calculated using two-tailed homoscedastic t-  
414 tests.

415

#### 416 *Model equations*

417 The equations for the computational model are as follows:

$$\frac{du_h}{dT} = a_1\lambda_d(u_{h-1} - 2u_h + u_{h+1}) + a_2\beta(x)\frac{w_h}{\kappa + w_h} - a_3\gamma u_h \quad (2)$$

$$\frac{dw_h}{dT} = a_4\lambda_{dc}(w_{h-1} - 2w_h + w_{h+1}) - a_5\beta(x)\frac{w_h}{\kappa + w_h} + a_6\gamma u_h \quad (3)$$

418 Where  $\beta(x) = \beta^o \exp\left(-x/\phi\right)^2$  represents the gaussian Toll-mediated rate constant and  $\kappa$  represents  
419 the Michaelis Menten constant for the dissociation of DI/Cact complex;  $u$  and  $w$  represent cytoplasmic  
420 species DI and DI/Cact complex respectively; subscript  $h$  represents a nucleus and its associated

421 cytoplasmic compartment;  $\lambda_i$  represents effective intercompartmental exchange rates; and the  $\alpha_i$ 's are  
422 weighting factors related to the nuclear import/export equilibrium constants and the geometry of the  
423 nucleus and cytoplasm (see Supplementary Information for more details).  
424 Equations (2-3) above have been derived after simplifying a more detailed model (see Supplementary  
425 information for details). The nuclei are modeled as spheres sitting in cuboidal cytoplasmic compartments  
426 that span the periphery of the embryo. Since the embryo is approximately symmetric about the DV axis;  
427 the spatial coordinate was varied from 0 to 1 with the former representing the ventral midline and the  
428 latter, the dorsal midline. The number of such compartments/nuclei/cells is taken to be 51, approximately  
429 equal to the number of nuclei in NC 14 found from live fluorescence imaging [20]. Both nuclei and the  
430 cytoplasm volumes are considered well mixed. We assume that the nucleus and cytoplasm are in a state  
431 of pseudo-equilibrium. Thus,  $k_{out}C_{nuc} \approx k_{in}C_{cyt}$  or  $C_{nuc} \approx K_{eq}C_{cyt}$  where,  $K_{eq} \equiv k_{in}/k_{out}$  is defined  
432 as the equilibrium constant for nuclear import/export for all species. The effect of Toll was modeled with  
433 a Michaelis Menten formulation, assuming the concentration of the intermediate species DI-Cact-Toll to  
434 be approximately constant in nuclear cycle 14. The above equations were then non-dimensionalized,  
435 approximately with respect to the conditions found in wildtype *Drosophila* embryos at the beginning of  
436 NC 14, such that every term was of order 1. The ratio of effective diffusivities or the length scale ratio was  
437 then defined as

$$\rho = \frac{\lambda_{dc}}{\tilde{V}_{nuc}K_{eq,dc} + \tilde{V}_{cyt}} / \frac{\lambda_d}{\tilde{V}_{nuc}K_{eq,d} + \tilde{V}_{cyt}} \quad (4)$$

438 where  $\tilde{V}_{nuc/cyt} = \frac{V_{nuc/cyt}}{\widehat{V}_{14}}$  (see Supplementary information for details).

439 The simulation was run for 60 min, which approximates the time period of NC 14, which is the longest  
440 nuclear cycle of the blastoderm. Dosage was varied by doubling or halving the initial concentration of  
441 DI/Cact. The dimensionless constants obtained from it were then varied from 1e-3 to 1e+3 to obtain

442 concentration profiles for DI and DI/Cact. From these concentration profiles, the dorsal border of *sna* and  
443 the ventral and dorsal borders of *sog* were calculated assuming the borders are defined by thresholds of  
444 free DI concentration. These model predictions of the borders were compared with experimental values  
445 in the least square error sense and parameter sets with errors lower than a set value were accepted as  
446 robust (see Supplementary information for details).

447

448 **References**

- 449 1. Ashe HL, Briscoe J. The interpretation of morphogen gradients. *Development*. 2006;133: 385–394.  
450 doi:10.1242/dev.02238
- 451 2. Houchmandzadeh B, Wieschaus E, Leibler S. Establishment of developmental precision and  
452 proportions in the early *Drosophila* embryo. *Nature*. 2002;415: 798–802. doi:10.1038/415798a
- 453 3. Eldar A, Rosin D, Shilo BZ, Barkai N. Self-enhanced ligand degradation underlies robustness of  
454 morphogen gradients. *Dev Cell*. 2003;5: 635–646. doi:10.1016/S1534-5807(03)00292-2
- 455 4. Lander AD, Lo W-C, Nie Q, Wan FYM. The Measure of Success: Constraints, Objectives, and  
456 Tradeoffs in Morphogen-mediated Patterning. *Cold Spring Harb Perspect Biol*. 2009;1: a002022.  
457 doi:10.1101/cshperspect.a002022
- 458 5. Liberman LM, Reeves GT, Stathopoulos A. Quantitative imaging of the Dorsal nuclear gradient  
459 reveals limitations to threshold-dependent patterning in *Drosophila*. *Proc Natl Acad Sci U S A*.  
460 2009;106: 22317–22. doi:10.1073/pnas.0906227106
- 461 6. Wharton KA, Ray RP, Gelbart WM. An activity gradient of decapentaplegic is necessary for the  
462 specification of dorsal pattern elements in the *Drosophila* embryo. *Development*. 1993;117: 807–  
463 822.
- 464 7. Dorfman R, Shilo BZ. Biphasic activation of the BMP pathway patterns the *Drosophila* embryonic  
465 dorsal region. *Development*. 2001;128: 965–972.
- 466 8. Reeves GT, Kalifa R, Klein DE, Lemmon MA, Shvartsman SY. Computational analysis of EGFR  
467 inhibition by Argos. *Dev Biol*. 2005;284: 523–535. doi:10.1016/j.ydbio.2005.05.013
- 468 9. Tabata T, Takei Y. Morphogens, their identification and regulation. *Development*. 2004;131: 703–  
469 712. doi:10.1242/dev.01043

- 470 10. Dev A, Iyer S, Razani B, Cheng G. NF- $\kappa$ B and Innate Immunity. *NF- $\kappa$ B in Health and Disease*. 2010.  
471 pp. 115–143. doi:10.1007/82\_2010\_102
- 472 11. Tornatore L, Thotakura AK, Bennett J, Moretti M, Franzoso G. The nuclear factor kappa B signaling  
473 pathway: integrating metabolism with inflammation. *Trends Cell Biol.* 2012;22: 557–566.  
474 doi:10.1016/j.tcb.2012.08.001
- 475 12. Hoesel B, Schmid J a. The complexity of NF- $\kappa$ B signaling in inflammation and cancer. *Mol Cancer.*  
476 2013;12: 86. doi:10.1186/1476-4598-12-86
- 477 13. Liu T, Zhang L, Joo D, Sun S-C. NF- $\kappa$ B signaling in inflammation. *Signal Transduct Target Ther.*  
478 2017;2: 17023. doi:10.1038/sigtrans.2017.23
- 479 14. Xia Y, Shen S, Verma IM. NF- B, an Active Player in Human Cancers. *Cancer Immunol Res.* 2014;2:  
480 823–830. doi:10.1158/2326-6066.CIR-14-0112
- 481 15. Roth S, Stein D, Nüsslein-Volhard C. A gradient of nuclear localization of the dorsal protein  
482 determines dorsoventral pattern in the *Drosophila* embryo. *Cell.* 1989;59: 1189–1202.  
483 doi:10.1016/0092-8674(89)90774-5
- 484 16. Reeves GT, Stathopoulos A. Graded dorsal and differential gene regulation in the *Drosophila*  
485 embryo. *Cold Spring Harb Perspect Biol.* 2009;1: a000836. doi:10.1101/cshperspect.a000836
- 486 17. Moussian B, Roth S. Dorsoventral axis formation in the *Drosophila* embryo--shaping and  
487 transducing a morphogen gradient. *Curr Biol.* 2005;15: R887--R899.  
488 doi:10.1016/j.cub.2005.10.026
- 489 18. Rushlow CA, Shvartsman SY. Temporal dynamics, spatial range, and transcriptional interpretation  
490 of the Dorsal morphogen gradient [Internet]. *Current Opinion in Genetics and Development.*  
491 Elsevier Current Trends; 2012. pp. 542–546. doi:10.1016/j.gde.2012.08.005

- 492 19. Daigneault J, Klemetsaune L, Wasserman SA. The IRAK homolog Pelle is the functional counterpart  
493 of I $\kappa$ B kinase in the Drosophila Toll pathway. *PLoS One*. 2013;8: e75150.  
494 doi:10.1371/journal.pone.0075150
- 495 20. Reeves GT, Trisnadi N, Truong T V, Nahmad M, Katz S, Stathopoulos A. Dorsal-ventral gene  
496 expression in the Drosophila embryo reflects the dynamics and precision of the dorsal nuclear  
497 gradient. *Dev Cell*. 2012;22: 544–57. doi:10.1016/j.devcel.2011.12.007
- 498 21. DeLotto R, DeLotto Y, Steward R, Lippincott-Schwartz J. Nucleocytoplasmic shuttling mediates the  
499 dynamic maintenance of nuclear Dorsal levels during Drosophila embryogenesis. *Development*.  
500 2007;134: 4233–41. doi:10.1242/dev.010934
- 501 22. O’Connell MD, Reeves GT. The presence of nuclear cactus in the early drosophila embryo may  
502 extend the dynamic range of the dorsal gradient. Baker RE, editor. *PLoS Comput Biol*. 2015;11:  
503 e1004159. doi:10.1371/journal.pcbi.1004159
- 504 23. Stathopoulos A, Levine M. Genomic Regulatory Networks and Animal Development. 2005;9: 449–  
505 462. doi:10.1016/j.devcel.2005.09.005
- 506 24. Ambrosi P, Chahda JS, Koslen HR, Chiel HJ, Mizutani CM. Modeling of the Dorsal Gradient across  
507 Species Reveals Interaction between Embryo Morphology and Toll Signaling Pathway during  
508 Evolution. *PLoS Comput Biol*. 2014; doi:10.1371/journal.pcbi.1003807
- 509 25. Chung K, Kim Y, Kanodia JS, Gong E, Shvartsman SY, Lu H. A microfluidic array for large-scale  
510 ordering and orientation of embryos. *Nat Methods*. 2011;8: 171–6. doi:10.1038/nmeth.1548
- 511 26. Carrell SN, O’Connell MD, Jacobsen T, Pomeroy AE, Hayes SM, Reeves GT. A facilitated diffusion  
512 mechanism establishes the Drosophila Dorsal gradient. *Development*. 2017;144: 4450–4461.  
513 doi:10.1242/dev.155549



- 514 27. Nusslein-Volhard C. Maternal Effect Mutations that Alter the Spatial Coordinates of the Embryo of  
515 *Drosophila melanogaster*. Determinants of Spatial Organization. Elsevier; 1979. pp. 185–211.  
516 doi:10.1016/B978-0-12-612983-0.50016-X
- 517 28. Nüsslein-Volhard C, Lohs-Schardin M, Sander K, Cremer C. A dorso-ventral shift of embryonic  
518 primordia in a new maternal-effect mutant of *Drosophila*. *Nature*. 1980;283: 474–476.  
519 doi:10.1038/283474a0
- 520 29. Govind S, Brennan L, Steward R. Homeostatic balance between Dorsal and Cactus proteins in the  
521 *Drosophila* embryo. *Development*. 1993;117: 135–148.
- 522 30. Kanodia JS, Rikhy R, Kim Y, Lund VK, DeLotto R, Lippincott-Schwartz J, et al. Dynamics of the Dorsal  
523 morphogen gradient. *Proc Natl Acad Sci U S A*. 2009;106: 21707–12.  
524 doi:10.1073/pnas.0912395106
- 525 31. Lander AD, Lo W, Nie Q. *The Measure of Success : Constraints , Objectives ,*. Spring. 2009;  
526 doi:10.1101/cshperspect.a002022
- 527 32. Lander AD. How Cells Know Where They Are. *SciencemagOrgEzp-Prod1HulHarvardEdu*. 2013;923.  
528 doi:10.1126/science.1224186
- 529 33. Lo W-C, Zhou S, Wan FY-M, Lander AD, Nie Q. Robust and precise morphogen-mediated patterning:  
530 trade-offs, constraints and mechanisms. *J R Soc Interface*. 2015;12. doi:10.1098/rsif.2014.1041
- 531 34. Kosman D, Mizutani CM, Lemons D, Cox WG, McGinnis W, Bier E. Multiplex detection of RNA  
532 expression in *Drosophila* embryos. *Science (80- )*. 2004;305: 846. doi:10.1126/science.1099247
- 533 35. Carrell SN, Reeves GT. Imaging the dorsal-ventral axis of live and fixed *Drosophila melanogaster*  
534 embryos. In: Nelson CM, editor. *Tissue Morphogenesis*. Springer New York; 2015. pp. 63–78.  
535 doi:10.1007/978-1-4939-1164-6

536 36. Trisnadi N, Altinok A, Stathopoulos A, Reeves GT. Image analysis and empirical modeling of gene  
537 and protein expression. *Methods*. 2013;62: 68–78. doi:10.1016/J.YMETH.2012.09.016


538

539

540 **Supporting information**


541 S1 File. This file contains details of methodology.

542 **Figures and tables**



544 **Figure 1:** The protein Dorsal patterns the DV axis of the *Drosophila* embryo. (A) An antibody staining against Dorsal  
545 in an NC 14 embryo. (B) mRNA expression of Dorsal target genes *sna* (magenta) and *sog* (green). (C) Illustration of  
546 the borders of gene expression. We use these borders to quantify and compare the extent of domain of dl target  
547 genes. Embryo cross-sections are oriented so that ventral is down.

548




549

550 **Figure 2:** Theoretical consideration of the sensitivity coefficient. (A) Testing whether a lower value of the parameter  
551  $b$  could result in a lower sensitivity. (B) The empirical prediction shows that 1x embryos completely lose *sna*  
552 expression, while 4x embryos have an overexpanded domain of *sna*, and lose *dpp* completely. (C) The prediction  
553 when lower  $b$  values were used.

554

555




556

557 **Figure 3:** Varying the maternal *dl* dose influences gene expression. (A) Box-and-violin plot of the ventral border of  
558 *sog*. (B) Box-and-violin plot of the dorsal border of *sog*. (C) Box-and-violin plot of the of the dorsal border of *sna*. The  
559 numbers above or below distributions indicate sample size Numbers between distributions indicate p-value; n.s. =  
560 “not significant”. Plus signs indicate statistical outliers.

561


562



563

564 **Figure 4:** Varying the maternal *dl* dose influences the DI gradient. (A) Averaged and normalized DI gradients in 1x,  
565 2x, and 4x embryos. Averaged from  $n > 10$  embryos. (B) Box-and-violin plot of the width of the Dorsal gradient in the  
566 genotypes shown in (A). Numbers below distributions indicate sample size. Numbers above indicate p-values. (C)  
567 Graph of DI gradients with best-fit amplitudes for the 1x and 4x gradients, with respect to the 2x gradient set to  
568 amplitude of one. (D) Contour plot of the SSE with respect to the amplitude of the 1x gradient ( $\alpha_{1x}$ ) and that of the  
569 4x gradient  $\alpha_{4x}$ . Red dot: the set of best-fit amplitudes. Red curves show the contours of the objective function  
570 landscape.

571



572

573 **Figure 5:** Computational results. (A). Concentration distribution of free DI for one of the robust parameter sets for  
 574 dosage 1x,2x and 4x. (B). Cumulative distribution plot for length scale ratio ( $\rho$ ) (C). Cumulative distribution plot of  
 575 the Michaelis Menten constant ( $\kappa$ ) (D). Plot of Amplitude ratio 1x/2x against length scale ratio (E). Plot of Amplitude  
 576 ration 2x/4x against length scale ratio (F). Plot of Amplitude ratio 1x/2x against  $\kappa$  (G). Plot of length scale ratio 2x/4x  
 577 against  $\kappa$ .

578



579 **Table 1:** Average gene expression locations or DI gradient widths in 1x, 2x, and 4x embryos. The percent columns  
580 are the absolute percent change from wildtype.

Property	1x	1x (%)	2x (wt)	4x	4x (%)
<i>sna</i> boundary	0.17	14	0.2	0.19	4
<i>sog</i> ventral boundary	0.17	11	0.19	0.21	10
<i>sog</i> dorsal boundary	0.45	5	0.47	0.51	8
DI gradient width	0.13	15	0.15	0.17	11

581

582